Daniela Bartoletti
Istituto di Ematologia di Bologna(IT)University of Bologna(IT)
Publications by Year
Research Areas
Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, Acute Myeloid Leukemia Research, Eosinophilic Disorders and Syndromes, Platelet Disorders and Treatments
Most-Cited Works
- → Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis(2019)145 cited
- → Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis(2021)69 cited
- → Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives(2022)63 cited
- → Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia(2021)53 cited
- → Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome(2023)38 cited
- → Second primary malignancy in myelofibrosis patients treated with ruxolitinib(2020)34 cited
- → The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis(2020)33 cited
- → Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients(2018)33 cited
- → Epidemiological trends of pediatric IBD in Italy: A 10-year analysis of the Italian society of pediatric gastroenterology, hepatology and nutrition registry(2022)33 cited
- → Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎(2018)29 cited